HCHF
15.5.2020 20:50:06 CEST | Business Wire | Press release
The world has witnessed what is described as an unprecedented historic scene on Thursday, 14th May, when millions of people around the world united in prayer to supplicate to God for an end to the COVID-19 pandemic and to help scientists and researchers find a vaccine against the disease as quickly as possible.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200515005533/en/
This came in response to the Higher Committee of Human Fraternity (HCHF) humanitarian call, which was blessed and supported by His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Head of the Catholic Church, and received the support of a number of kings, presidents, leaders, and leading political, religious, and media figures from all over the world.
The HCHF’s call to pray for humanity, which was announced in a statement issued in 14 languages, gained momentum on social media platforms, as the initiative recorded 36 billion cumulative digital media interactions, engagement and potential reach as estimated by Talkwalker analytics report, since it was launched on 2nd May till 15th May. The initiative’s official website (pray.forhumanfraternity.org) and social media accounts have hosted a 24-hour livestream for the global prayers.
#PrayForHumanity hashtag trended on social media in many countries, including France, Germany, India, KSA, UAE, Spain, Egypt, and Italy, reflecting the great success of the initiative which also attracted the attention of global media.
The HCHF extended thanks to all leaders, religious, political, and popular institutions, and all those who participated in the global prayer day.
Judge Mohamed Abdel Salam, HCHF Secretary-General, praised the unexpected successes of the initiative, stressing that such successes will contribute to achieving a true global unity.
He said: “The voices of supplications to God that were made in an unprecedented humanitarian scene in all continents of the world to end this pandemic are reasons for us to feel optimistic and give us confidence that our unity will help the world overcome this crisis.”
Monsignor Yoannis Lahzi Gaid, Personal Secretary to His Holiness Pope Francis, stated that the participation of different religions and beliefs in this initiative also the global response paves a way forward to continue working for humanity, especially in facing this pandemic. He said: “We will keep supplicating to God and work with our brothers from different religions and beliefs to transform this suffering to an opportunity for more solidarity and fraternity.”
The HCHF is an independent international committee that includes a group of experts and leaders in inter-culture communication and interfaith dialogue. It aims to achieve the higher goals for human fraternity signed by His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Head of the Catholic Church, in Abu Dhabi in February 2019, under the patronage of HH Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi, the patron of the Document on Human Fraternity.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20200515005533/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom